Replimune Group Reports Increased Losses Amid R&D Expansion

Replimune Group ( (REPL) ) has released its Q2 earnings. Here is a breakdown of the information Replimune Group presented to its investors.

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies to treat cancer, leveraging a novel strain of herpes simplex virus 1 to activate the immune system against tumors. In its latest earnings report for the quarter ending September 30, 2025, Replimune reported a net loss of $83.1 million, compared to a $53.1 million loss in the same period last year, reflecting increased research and development expenses as well as selling, general, and administrative costs. The company’s cash and cash equivalents stood at $102.3 million, with short-term investments totaling $221.3 million, indicating a decrease in total current assets from the previous quarter. Despite the financial losses, Replimune continues to advance its RPx product candidates, with RP1 being the most advanced in clinical trials for melanoma. Looking ahead, Replimune’s management remains focused on achieving regulatory milestones and advancing its pipeline, while acknowledging the need for additional capital to support ongoing operations and potential commercialization efforts.